EWA
ALXN

Evolution Wealth Advisors’s Alexion Pharmaceuticals ALXN Stock Holding History

Evolution Wealth Advisors’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-30
Closed -$6K – 698
2021
Q2 		$6K Sell
30
-71
-70% -$12.2K ﹤0.01% 491
2021
Q1 		$15K Sell
101
-173
-63% -$26.8K ﹤0.01% 350
2020
Q4 		$43K Buy
274
+14
+5% +$1.8K 0.01% 189
2020
Q3 		$30K Buy
260
+230
+767% +$24.8K 0.01% 234
2020
Q2 		$3K Buy
+30
New +$3.19K ﹤0.01% 461
2019
Q3 		– Sell
-173
Closed -$23K – 608
2019
Q2 		$23K Buy
+173
New +$22.3K 0.01% 121

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $280B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return